Anti-IL-17 therapy in treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials

A Study to Evaluate the Safety, Tolerability, and Efficacy of Brodalumab in Subjects with Rheumatoid Arthritis and an Inadequate Response to Methotrexate

(2015) K. Pavelka et al.   JOURNAL OF RHEUMATOLOGY

Association ofHLA-DRB1alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis

(2015) Gerd R. Burmester et al.   RHEUMATOLOGY

Comparative efficacy and safety of tofacitinib, with or without methotrexate, in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials

(2015) Young Ho Lee et al.   RHEUMATOLOGY INTERNATIONAL

Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholds

(2014) Vibeke Strand et al.   Health and Quality of Life Outcomes

Pharmacokinetic-pharmacodynamic modeling of fostamatinib efficacy on ACR20 to support dose selection in patients with rheumatoid arthritis (RA)

(2014) John Maringwa et al.   JOURNAL OF CLINICAL PHARMACOLOGY

One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study

(2014) M. C. Genovese et al.   JOURNAL OF RHEUMATOLOGY

A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis

(2014) Kenneth B. Gordon et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis

(2014) Philip J. Mease et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-associated cell targets

(2014) D. E. Furst et al.   RHEUMATOLOGY

Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy?

(2014) Lisa GM van Baarsen et al.   ARTHRITIS RESEARCH & THERAPY

A Phase II Randomized Study of Subcutaneous Ixekizumab, an Anti-Interleukin-17 Monoclonal Antibody, in Rheumatoid Arthritis Patients Who Were Naive to Biologic Agents or Had an Inadequate Response to Tumor Necrosis Factor Inhibitors

(2014) Mark C. Genovese et al.   Arthritis & Rheumatology

Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial

(2013) Dominique Baeten et al.   LANCET

A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis

(2013) David A Martin et al.   ARTHRITIS RESEARCH & THERAPY

Incomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway

(2012) Saba Alzabin et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study

(2012) Mark C Genovese et al.   ANNALS OF THE RHEUMATIC DISEASES

2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

(2012) Jasvinder A. Singh et al.   ARTHRITIS CARE & RESEARCH

T cell lessons from the rheumatoid arthritis synovium SCID mouse model: CD3-rich synovium lacks response to CTLA-4ig but is successfully treated by interleukin-17 neutralization

(2011) Marije I. Koenders et al.   ARTHRITIS AND RHEUMATISM

Interleukin-23: as a drug target for autoimmune inflammatory diseases

(2011) Chunlei Tang et al.   IMMUNOLOGY

LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study

(2010) M. C. Genovese et al.   ARTHRITIS AND RHEUMATISM

Role of Th17 cells in human autoimmune arthritis

(2010) Jan Leipe et al.   ARTHRITIS AND RHEUMATISM

Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors

(2010) Devesh Mewar et al.   BRITISH JOURNAL OF PHARMACOLOGY

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

(2010) W. Hueber et al.   Science Translational Medicine

Description of the Efficacy and Safety of Three New Biologics in the Treatment of Rheumatoid Arthritis

(2010) Steven S. Storage et al.   KOREAN JOURNAL OF INTERNAL MEDICINE

IL-17 and Th17 Cells

(2009) Thomas Korn et al.   Annual Review of Immunology

Structural basis of receptor sharing by interleukin 17 cytokines

(2009) Lauren K Ely et al.   NATURE IMMUNOLOGY

IL-17 as a future therapeutic target for rheumatoid arthritis

(2009) Wim B. van den Berg et al.   Nature Reviews Rheumatology

Interleukin-17 and Type 17 Helper T Cells

(2009) Pierre Miossec et al.   NEW ENGLAND JOURNAL OF MEDICINE

IL-17/Th17 targeting: On the road to prevent chronic destructive arthritis?

(2007) Erik Lubberts   CYTOKINE